EP Vantage
Contributor since: 2008
Company: EP Vantage
Latest Articles
Upcoming Events - Late-Stage Data Due For Amicus And Insmed
Surprisingly Broad Lynparza Approval Levels The Playing Field
Snippet Roundup: Transparency For Straumann But A Black Box For Pfizer
Novo And Lilly Head For Diabetes Pricing Battle
Biogen's Alzheimer's Hope Tops The Sector's Most Valuable Pipeline Projects
Opdivo's Renal Failure Boosts Exelixis - Or Does It?
Hansa Gears Up In Kidney Transplant
As Zytiga's Importance Grows, So Does That Of Generics
The Balloon Goes Up For Apollo And Reshape
Alnylam Shoots For The Moon With Apollo
Fibrogen And Galapagos Raise Lung Disease Hopes
Ionis Absorbs Glaxo Rare Disease Cull
Sage And Ablynx Look To Their Lead Assets
Snippet Roundup: A Small Success For Galapagos And A Big One For Karius
Rebiotix Tries To Get One Up Over Seres
Viral Success For Grail But Not With Core Tech
Looking Beyond Factors In Hemophilia
Cempra And Melinta's Lesson In Value Destruction
Dermira Grabs Big Pharma Castoff
Positive Triplet Data Should Accelerate Esperion Deal-Making Chatter
Does Roche Have The Hemophilia X Factor?
GW Approaches Crunch Time
Dupixent Asthma Data Could Seal A Second Blockbuster Market
Pamrevlumab Comes Off The Bench To Deliver For Fibrogen
Fresenius Aims To Take Home Dialysis To The NxStage
Interview - Santhera Readies Muscular Dystrophy Push
Vantage View - Statistical Wars: A New Low
Upcoming Events - FDA Decision For Adamas In Parkinson's Dyskinesia And Growth Data For Versartis
Snippet Roundup: Two Approvals, Two Setbacks And A Price War
Bristol's Private Sting Should Have Venture Financiers Celebrating
Bonfire Of Teva-Nities
No Room For Neuroscience In New-Look Shire